Literature DB >> 16336017

Estimating mean total costs in the presence of censoring: a comparative assessment of methods.

Tracey A Young1.   

Abstract

INTRODUCTION: Frequently, within economic evaluations, data are subject to censoring, and ignoring censored data will lead to an underestimation of mean total costs. Several techniques have been published that can be used to estimate mean total costs and standard errors, and allow for censoring within cost data. This paper reviews these techniques and compares the mean total costs estimates generated by each method for different types of censoring.
METHODS: Nine techniques were identified that can be used to estimate mean total costs and standard errors in the presence of censoring: ignoring censoring; ignoring censored costs; Lin's method--with and without cost histories; weighted cost method--with and without cost histories; Lin's regression method--with and without cost histories; and Carides' regression method. These methods are compared across four different censoring mechanisms--random censoring, end-of-study censoring, informative censoring and partial censoring--by simulating the censoring mechanisms from a complete cohort of patients included in the CELT (Cost Effectiveness of Liver Transplantation) study.
RESULTS: The observed mean cost and standard error from the CELT data were 36,045 pounds sterling and 1517 pounds sterling (1998 values). Estimates under informative censoring were the least accurate predictors of mean total costs and tended to overestimate mean costs by > 1000 pounds sterling. Carides' regression method predicted mean total costs to within 3 pounds sterling of the observed mean and represented one of the three most accurate methods for predicting mean total costs (together with the weighted cost method with known cost histories and Lin's method with unknown cost histories). Lin's method with known cost histories gave the least accurate estimates of mean total costs and underpredicted costs by 2137-4859 pounds sterling across censoring mechanisms. Carides' method did not predict uncertainty around the mean costs well, and the weighted cost method with known cost histories and ignoring censoring were the best methods to use for estimating the standard error of the mean cost.
CONCLUSIONS: Further work should be carried out on other datasets to confirm the generalisability of these results. Although Carides' regression method and Lin's method with unknown cost histories were the best estimators of mean total costs across censoring mechanisms, the weighted cost method with known cost histories is the preferred method for obtaining an accurate estimate of the mean total cost alone and the uncertainty surrounding it; therefore, it should be used to estimate mean costs and standard errors when patient cost histories are known.

Entities:  

Mesh:

Year:  2005        PMID: 16336017     DOI: 10.2165/00019053-200523120-00007

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  12 in total

1.  A regression-based method for estimating mean treatment cost in the presence of right-censoring.

Authors:  G W Carides; J F Heyse; B Iglewicz
Journal:  Biostatistics       Date:  2000-09       Impact factor: 5.899

2.  On estimators of medical costs with censored data.

Authors:  Anthony O'Hagan; John W Stevens
Journal:  J Health Econ       Date:  2004-05       Impact factor: 3.883

3.  Estimating medical care costs under conditions of censoring.

Authors:  M Raikou; A McGuire
Journal:  J Health Econ       Date:  2004-05       Impact factor: 3.883

4.  Modelling programme costs in economic evaluation.

Authors:  P Fenn; A McGuire; M Backhouse; D Jones
Journal:  J Health Econ       Date:  1996-02       Impact factor: 3.883

5.  On estimating costs for economic evaluation in failure time studies.

Authors:  A P Hallstrom; S D Sullivan
Journal:  Med Care       Date:  1998-03       Impact factor: 2.983

6.  Estimating medical costs from incomplete follow-up data.

Authors:  D Y Lin; E J Feuer; R Etzioni; Y Wax
Journal:  Biometrics       Date:  1997-06       Impact factor: 2.571

7.  The analysis of censored treatment cost data in economic evaluation.

Authors:  P Fenn; A McGuire; V Phillips; M Backhouse; D Jones
Journal:  Med Care       Date:  1995-08       Impact factor: 2.983

8.  Estimating the costs attributable to a disease with application to ovarian cancer.

Authors:  R Etzioni; N Urban; M Baker
Journal:  J Clin Epidemiol       Date:  1996-01       Impact factor: 6.437

9.  Methods to analyse cost data of patients who withdraw in a clinical trial setting.

Authors:  Jan B Oostenbrink; Maiwenn J Al; Maureen P M H Rutten-van Mölken
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

10.  Midterm cost-effectiveness of the liver transplantation program of England and Wales for three disease groups.

Authors:  Louise Longworth; Tracey Young; Martin J Buxton; Julie Ratcliffe; James Neuberger; Andrew Burroughs; Stirling Bryan
Journal:  Liver Transpl       Date:  2003-12       Impact factor: 5.799

View more
  16 in total

1.  Estimating 'costs' for cost-effectiveness analysis.

Authors:  Alec Miners
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

2.  Cost-effectiveness of pazopanib in advanced soft-tissue sarcoma in Canada.

Authors:  T E Delea; J Amdahl; H R Nakhaipour; S C Manson; A Wang; N Fedor; A Chit
Journal:  Curr Oncol       Date:  2014-12       Impact factor: 3.677

Review 3.  An Educational Review About Using Cost Data for the Purpose of Cost-Effectiveness Analysis.

Authors:  Matthew Franklin; James Lomas; Simon Walker; Tracey Young
Journal:  Pharmacoeconomics       Date:  2019-05       Impact factor: 4.981

4.  Nonparametric inference for median costs with censored data.

Authors:  Hongwei Zhao; Chen Zuo; Shuai Chen; Heejung Bang
Journal:  Biometrics       Date:  2012-02-24       Impact factor: 2.571

5.  Cost-effectiveness analysis: a proposal of new reporting standards in statistical analysis.

Authors:  Heejung Bang; Hongwei Zhao
Journal:  J Biopharm Stat       Date:  2014       Impact factor: 1.051

6.  Sourcing and Using Appropriate Health State Utility Values in Economic Models in Health Care.

Authors:  Roberta Ara; Tessa Peasgood; Clara Mukuria; Helene Chevrou-Severac; Donna Rowen; Ismail Azzabi-Zouraq; Suzy Paisley; Tracey Young; Ben van Hout; John Brazier
Journal:  Pharmacoeconomics       Date:  2017-12       Impact factor: 4.981

Review 7.  Multiple chronic conditions and healthcare costs among adults.

Authors:  Usha Sambamoorthi; Xi Tan; Arijita Deb
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2015       Impact factor: 2.217

8.  Economic evaluation of treating clinically isolated syndrome and subsequent multiple sclerosis with interferon beta-1b.

Authors:  Carlo Lazzaro; Cosetta Bianchi; Lucia Peracino; Paola Zacchetti; Antonio Uccelli
Journal:  Neurol Sci       Date:  2009-01-24       Impact factor: 3.307

9.  Predicting hospital costs for patients receiving renal replacement therapy to inform an economic evaluation.

Authors:  Bernadette Li; John Cairns; James Fotheringham; Rommel Ravanan
Journal:  Eur J Health Econ       Date:  2015-07-08

10.  Impact on Medical Cost, Cumulative Survival, and Cost-Effectiveness of Adding Rituximab to First-Line Chemotherapy for Follicular Lymphoma in Elderly Patients: An Observational Cohort Study Based on SEER-Medicare.

Authors:  Robert I Griffiths; Michelle L Gleeson; Joseph Mikhael; Mark D Danese
Journal:  J Cancer Epidemiol       Date:  2012-08-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.